WHO Emphasizes Importance Of R&D For Drug-Resistant TB After Excluding Disease From List Of Priority Drug-Resistant Bacteria

Science Speaks: TB partners, patients ask: How does a bacterium responsible for nearly a third of drug-resistance deaths not make list of R&D priority pathogens?
“The day after the World Health Organization announced it had produced its ‘first ever’ list of drug-resistant bacteria for which new medicines are the most urgently needed, the agency released a second announcement on the topic Tuesday, emphasizing its recognition of drug-resistant tuberculosis, which had been left off the list, as ‘a top priority for WHO and for the world’…” (Barton, 3/1).

U.N. News Centre: Drug-resistant tuberculosis continues to be serious health threat says U.N. health agency
“…According to the World Health Organization (WHO), in the past 50 years, only two new antibiotics addressing drug-resistant tuberculosis have made it to the third phase of trials. … ‘Addressing drug-resistant tuberculosis research is a top priority for WHO and for the world,’ says WHO Director-General Margaret Chan. ‘More than $800 million per year is currently necessary to fund badly needed research into new antibiotics to treat tuberculosis’…” (3/1).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.